The Columbia River Oncology Program (CROP), a Community Clinical Oncology Program (CCOP) currently in its 22nd year, is a consortium of four health care systems in the metropolitan Portland, Oregon/Vancouver, Washington area. These health care systems encompass: Adventist Medical Center, Legacy Health System, Providence Health System, and Southwest Washington Medical Center. CROP'S specific aims are: 1) Enhance the health of our community by providing and promoting cancer treatment, cancer prevention and cancer control research studies, 2) Seek opportunities to mirror the diversity of our community by providing complementary and holistic clinical research studies, 3) Advocate for and participate in clinical trials providing symptom management, improved quality of life, and palliative care for our cancer patient population, 4) Increase our physician alliances and commitments to clinical trials and increase accrual goals, and 5) Expand participation of minorities and the underserved population to participate in cancer prevention, cancer control and treatment studies. CROP currently affiliates with seven research bases: COG, MDACC, NCCTG, NSABP, RTOG, SWOG, and URCC. All are multi-specialty cooperative groups that supply CROP with NCI approved cancer prevention, cancer control and cancer treatment protocols. The established functioning operational status of CROP includes an Executive Board with representative committee structure, a central office, and actively participating hospital systems. The central office staff coordinates the administrative aspects of CROP, the large cancer prevention studies and quality improvement activities. The Clinical Trial Nurses and Clinical Research Associates employed by the consortium hospitals recruit patients to cancer control and treatment protocols collect and submit data to the research bases, participate in the quality improvement process, and actively participate in the research base meetings. Each organization employs a pharmacist to manage the investigational agents for CROP.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA045377-23
Application #
7658383
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1987-08-28
Project End
2014-05-31
Budget Start
2009-08-01
Budget End
2010-05-31
Support Year
23
Fiscal Year
2009
Total Cost
$745,543
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
099142093
City
Portland
State
OR
Country
United States
Zip Code
97213
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 142 publications